Programmed cell death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies ...

This study will focus on the treatment of newly diagnosed locally advanced primary head and neck cancer patients with no ...

If you have NSCLC, some cancer cells may churn out a protein called PD-L1. It attaches to another protein, PD-1, on important immune T cells. This is called an immune checkpoint, and it tells your ...

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses.

Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category, but picked up its first approval in the rare tumour Merkel cell carcinoma ... be the new standard of cancer for SCAC as POD1UM ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of ...

Abstracts will be made available on the ESMO I-O website on 5 December 2024 at 00:05 CET. The poster containing new data, not in the abstract, will be available on the Posters & Publications section ...

including melanoma and non-small cell lung cancer (NSCLC), over six months. The main aim of the study is to assess the safety of mRNA-4359 and its ability to stimulate antibodies against PD-L1 and ...

Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway are widely used in cancer immunotherapy, but poor tissue distribution or immune-related adverse events often limit their application.

NEW YORK – Akeso Biopharma on Wednesday said it dosed the first patient with PD-L1-positive advanced head and neck cancer in a Phase III trial, comparing the activity of its PD-1/VEGF bispecific ...

Study results have been published in The Lancet Oncology and Nature Cancer, and have been presented at multiple ... dependent cellular phagocytosis (ADCP) by cross-linking PD-L1 expressing tumor cells ...